Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft

Next Previous
Trial Profile

A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orca-T (Primary) ; Methotrexate; Tacrolimus
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Precision-T
  • Sponsors Orca Bio

Most Recent Events

  • 02 Mar 2026 According to an Orca Bio media release, data from the trial will be presented in oral and poster sessions at the 52nd Annual Meeting of the EBMT from March 22-25 in Madrid.
  • 15 Dec 2025 According to an Orca Bio media release, company announced the publication of phase 3 Precision-T study data for Orca-T in Blood, the journal of the American Society of Hematology (ASH).
  • 06 Dec 2025 According Orca Bio media release, data from this study presented at the 67th American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top